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Carcinosarcoma is a rare biphasic neoplasia containing both malignant mesenchymal and epithelial elements. Bladder
carcinosarcoma commonly presented as high-grade, advanced stage, and aggressive behavior with a poor prognosis. An 83-year-
old male presented with painless gross hematuria to our hospital. Cystoscopy revealed massive nonpapillary bladder tumor on
the right wall. The 91g tumor could be completely removed with transurethral resection. Histology of the tumor was diagnosed
as carcinosarcoma with no submucosal invasion composed of biphasic malignant epithelial and mesenchymal cells. Epithelial
malignancy was urothelial cancer and mesenchymal one was chondrosarcoma and leiomyosarcoma. The specimens taken at the
second-look TUR-Bt revealed that carcinoma in situ (urothelial cancer) but not sarcoma existed at the mucosa surrounding the
previous tumor site. 80mg of BCG instillation intravesically every week for six weeks was successfully administered to the patient.
There is no tumor recurrence for 6 months after treatments.
1.Introduction
Carcinosarcoma, also called true malignant mixed tumor,
is a rare biphasic neoplasia containing both malignant
mesenchymal and epithelial elements. Only 79 cases of
carcinosarcoma of bladder origin have been reported in the
English literature in the year of 2007 [1]. Bladder carcinosar-
coma commonly presented as high-grade, advanced stage,
and aggressive behavior with a poor prognosis [2].
The mesenchymal element of carcinosarcoma lacks
epithelial markers [3, 4] and patients with carcinosarcoma
present at a more advanced stage and are at greater risk
for death compared to patients with high-grade urothelial
carcinoma [5]. In a clinicopathological report analyzing 15
cases of bladder carcinosarcoma, chondrosarcoma in 3 cases,
leiomyosarcoma in 3, malignant ﬁbrous histiocytoma in 3,
osteosarcoma in 2, ﬁbrosarcoma in 1, rhabdomyosarcoma
in 1, and more than 1 type in 2 were demonstrated in the
sarcomatous component [3].
In cases of bladder carcinosarcoma, evidence supporting
a monoclonal origin for the epithelial and mesenchymal
componentswas revealedusing lossofheterozygosity studies
with microsatellite markers [6, 7], while there exists a
hypothesis that multiclonal stem cells of the epithelial
and mesenchymal components play a causative role. It is
also known that bladder carcinosarcoma develops following
cyclophosphamide therapy [6, 8]a sw e l la sr a d i o t h e r a p yt o
the bladder[9]. Here we report an interesting case of bladder
carcinosarcoma which was more than 10cm in diameter,
nevertheless it was without submucosal invasion.
2.Case Presentation
An83-year-oldmale presentedwith painlessgrosshematuria
to our hospital.Cystoscopy revealed massive nonpapillary
bladder tumor on the right wall. Pelvic CT scan showed a
giant bladdertumormorethan 10cmin diameter(Figure 1),
while there was no distant metastasis by abdominal and2 Case Reports in Medicine
Figure 1: Enhanced CT scan indicates a giant bladder tumor
(hematoxylin and eosin stain; an arrow indicates the tumor).
Figure 2: Epithelial malignancy is urothelial cancer without
submucosalinvasion(hematoxylin and eosin stain).
chest CT scans. There were no abnormalities in regular
laboratory tests. Fortunately, the tumor could be completely
removed with transurethral resection (TUR-Bt) and the
tumor base specimen was sampled with cold punch biopsies.
The resected tumor weight was 91g and blood transfusion
was unnecessary.
Histology of the tumor was diagnosed as carcinosarcoma
composedofbiphasic malignant epithelialand mesenchymal
cells. Epithelial malignancy was urothelial cancer (Figure 2)
and mesenchymal one was chondrosarcoma (Figure 3)a n d
leiomyosarcoma (Figures 4(a) and 4(b)). Broad neck of the
tumor was of urothelial cancer grade 2 > 3, and there was no
submucosal invasion (Figure 2). Specimen of the tumor base
containedmuscleﬁbersandshowed nomalignantcells there.
Immunohistochemistry showedthatcytokeratinwaspositive
only in epithelial malignancy but not in mesenchymal one
(data not shown).
Considering the noninvasive pathology of the tumor
despite well-known aggressive behavior of carcinosarcoma,
it was diﬃcult to judge if more invasive treatments such
as radical cystectomy or external beam radiation therapy +
interventional arterial infusion of anticancer drug(s) are
mandatory.Thus,second-lookTUR-Btwasdone7weeksfol-
lowing the ﬁrst TUR-Bt. The specimens taken at the second-
look TUR-Bt revealed that there was no remaining tumor
cells at the site where the previous tumor was resected by
Figure 3: One of the mesenchymal malignancies is chondrosar-
coma (hematoxylin and eosin stain).
(a)
(b)
Figure 4: (a) The other of the mesenchymal malignancies is
leiomyosarcoma (Hematoxylin and eosin stain). (b) Leiomyosar-
coma expressed smooth muscle actin (Immunohistochemistry).
the ﬁrst TUR-Bt, while carcinoma in situ (urothelial cancer)
but not sarcoma existed at the mucosa surrounding the
previous tumor site (data not shown). Then, we forwarded
to the intravesical BCG instillation therapy to the patient
and 80mg of BCG every week for six weeks was successfully
administered. Pelvic, abdominal, and chest CT scans as well
as cystoscopy and urine cytology have not shown tumor
recurrence for 6 months after treatments.Case Reports in Medicine 3
3.Discussion
Acaseofbladdersarcomatoidcarcinoma,whichwas resected
by TUR-Bt and diagnosed as nonmuscle invasive (pT1
stage), was previously reported to have shown intravesical
recurrence during followup, undergone partial and total
cystectomy, and ﬁnally died 13 months after diagnosis [10].
On the contrary, there was a case of bladder carcinosar-
coma which obtained pathologically complete response by
chemoradiotherapy [11].
In general, more aggressive therapies than TUR-Bt alone
areusuallyadoptedastreatmentsforbladdercarcinosarcoma
duetoinvasivenessofthetumor.ThepTstageofourcasewas
fortunately pTa without submucosal inﬁltration if we simply
apply the pathological staging system of bladder urothelial
cancer and the second-look TUR-Bt revealed carcinoma in
situ but not already invasive cancer/sarcoma, then we did
not perform radical cystectomy or chemoradiotherapy in
our case, but intravesical BCG instillation therapy trying
to preserve bladder. It might have been fortunate that the
tumor base was mainly composed of urothelial cancer but
not sarcoma, as the latter may often be more invasive than
the former. Of course, the patient naturally needs close
followup for tumor local recurrence and metastasis. CT
scans, cystoscopy, and urine cytology every three months
may be necessary during the ﬁrst year after treatment.
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